DFTXDefinium Therapeutics, Inc.
Is it safe?
Mostly sound, with a caveat: comfortable debt (AA), but big price swings.
Insiders were net sellers (-$3.0M, 90 days to Oct 8, 2026), selling is often routine.
Net cash and profitable. A rule of thumb on leverage, not a credit rating.
Large price swings, high volatility. Worst drawdown -100% · now 22% below its 52-week high.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can DFTX take a bad year?
Definium Therapeutics, Inc. holds $1.05B more cash than debt, so a bad year is a question about profits, not about lenders.
Net cash
- Net debt / EBITDA
- net cash
Net debt / EBITDA · no net borrowings to measure against earnings
- Interest cover
- none
Interest cover · no operating profit to pay the interest bill from
- Annualised volatility
- 78%
Annualised volatility · three times the market's own swing
Details›
- Total debtQ2 2026
- $36M
- Cash and short-term investments
- $1.08B
- Net cash
- $1.05B
- Operating profit, trailing twelve months
- −$228M
- Debt / equity
- 0.04×
- Annualised volatilitytwo years of daily moves
- 78%
- Worst drawdown on file
- −100%
- Below its 52-week high
- 22%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.